Introduction

24
Recent advances in inhalation therapy have provoked consid-25 erable interest in the development of novel formulations intended 26 for pulmonary delivery of macromolecules (Tamber et al., 2005) .
27
This is primarily due to the lung having a favourable environment formulations was determined at 0 h and after 24 h using the azo- 320 which is characteristic of spray dried products due to the rapid 410 drying of droplets (Corrigan, 1995) . Consequently, spray drying 411 parameters were set to preserve the outlet temperature in the range 412 of 44-47 • C due to the low melting of PEG-co-(PGA-co-PDL).
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260 d ae = d p p 1 , p 1 = 1 g cm −3(3)Viability (%) = A − S CM − S × 100(5)
413
Spray drying the emulsion formulations with l-leucine pro-414 duced dry powders with yields between 66.6 ± 7.1 and 88.8 ± 5.4%
415
( Table 1 The physical characteristics of spray dried microparticles (data represent mean ± SD, n = 3). * DCM alone vs CHF alone (p < 0.05, t-test/two-tailed). ** CHF/PEG4500, 6.7% vs CHF/PLF68, 3.4%, CHF/PEG4500, 1% and CHF/PEG4500, 3.4% (p < 0.05, ANOVA/Tukey's). # CHF alone vs CHF/PLF68, 1%, CHF/PLF68, 3.4%, CHF/PEG4500, 1%, CHF/PEG4500, 3.4% and CHF/PEG4500, 6.7% (p < 0.05, ANOVA/Dunnett). 
516
(p > 0.05, t-test/two-tailed) (Fig. 4C) . 4 . In vitro release of ␣-CH from spray dried microparticles in aqueous 1% w/v PLF68 medium, (A) microparticles prepared using DCM alone, CHF alone and different concentrations of PLF68 in the internal phase (w1) of double emulsion, (B) microparticles prepared using CHF alone and different concentrations PEG4500 in the internal phase (w1) of double emulsion and (C) in vitro release of ␣-CH and DNase I from microparticles prepared using CHF/PLF68, 1% in the internal phase (w1) of double emulsion (data represent mean ± SD, n = 3).
In this study the incorporation of PLF68 and PEG4500 in the (Table 2 ). This occurred due to the properties of PLF68 and PEG4500 Table 2 The bioactive fraction of ␣-CH released from different formulations at 0 h and after 24 h release in aqueous 1% w/v Pluronic ® F68 medium, determined using the azocasein assay (data represent mean ± SD, n = 3). 88.16 ± 3.55% cell viability) appeared to be well tolerated by normal Table 3 The aerosolization characteristics of spray dried ␣-CH encapsulated microparticles (data represent mean ± SD, n = 3). ies at 0 h and 24 h. The activity was found to be 90.1 ± 4.5% and 628 81.9 ± 2.7% respectively, compared to unprocessed DNase I. 
Conclusion
630
The findings from our investigations indicate that PEG-co-(PGA- phase, and this is followed by gradual release over 5 h in vitro. Liverpool John Moores University.
